Phase I Safety and Pharmacokinetics Study of Micronized Atovaquone in Human Immunodeficiency Virus-Infected Infants and Children

A phase I dose-escalating safety and pharmacokinetic study evaluated an oral suspension of micronized atovaquone (m-atovaquone) in infants and children stratified into age groups from 1 month to 12 years of age. Dosages of 10, 30, and 45 mg/kg of body weight/day were evaluated as single daily doses...

Olles dieđut

Bibliográfalaš dieđut

Publikašuvnnas:	Antimicrob Agents Chemother
Váldodahkkit:	Hughes, Walter, Dorenbaum, Alejandro, Yogev, Ram, Beauchamp, Belinda, Xu, Jing, McNamara, James, Moye, John, Purdue, Lynette, van Dyke, Russell, Rogers, Michael, Sadler, Brian, Group, The Pediatric Aids Clinical Trials
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	American Society for Microbiology (ASM) 1998
Fáttát:	Pharmacology
Liŋkkat:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC105594/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/9624466/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.42.6.1315
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!